NDA 216578 · Astellas
Veozah
Fezolinetant · Oral · Neurokinin 3 Receptor Antagonist
NovelPriority reviewCDER novel approval, May 12, 2023: To treat moderate to severe hot flashes caused by menopause
Last checked: Nov 20, 2026Latest source record: Dec 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
May 12, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
29
12 Phase 3, 8 recruiting
FAERS reports
2,301
466 serious, 5 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS OF HEPATOTOXICITY Hepatotoxicity has occurred with the use of VEOZAH in the postmarketing setting ( 5.1 ). • Perform hepatic laboratory tests prior to initiation of treatment to evaluate for hepatic function and injury. Do not start VEOZAH if either aminotransferase is ≥ 2 x the upper limit of normal (ULN) or if the total bilirubin is ≥ 2 x ULN for the evaluating laboratory. • Perform follow-up hepatic laboratory testing monthly for the first 3 months, at 6 months, and 9 months of treatment ( 2.1 , 5.1 ). • Advise patients to discontinue VEOZAH immediately and seek medical attention including hepatic laboratory tests if they experience signs or symptoms that may suggest liver injury (new onset fatigue, decreased appetite, nausea, vomiting, pruritus, jaundice, pale feces, dark urine, or abdominal pain) ( 2.1 , 5.1 ). • Discontinue VEOZAH if transaminase elevations are > 5...
What it is approved for
From the label in effect Feb 26, 2026.
VEOZAH ® is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. VEOZAH is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. ( 1 )
Mechanism: VEOZAH is a neurokinin 3 (NK3) receptor antagonist that blocks neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron to modulate neuronal activity in the thermoregulatory center. Fezolinetant has high affinity for the NK3 receptor (Ki value of 19.9 to 22.1 nmol/L), which is more than 450-fold higher than binding affinity to NK1 or NK2 receptors.
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 12, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
- VEOZAH · FEZOLINETANT 45MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fezolinetant" as an intervention, any sponsor and status, largest first.
- A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through MenopausePivotal-lookingCompleted
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT04003389 · 1,831 participants · Start Jul 10, 2019 · Primary completion Jan 4, 2022
Drug: fezolinetant; placebo · For: Hot Flashes
Sites: Andalusia, Alabama; Birmingham, Alabama; Ensley, Alabama · 182 sites in all
- A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone TherapyPivotal-lookingActive, not recruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT06440967 · 982 participants · Start Jul 31, 2024 · Primary completion Jun 25, 2026
Drug: Fezolinetant; Placebo and 2 more · For: Hot Flashes
Sites: Sarnia, Canada; Sault Ste. Marie, Canada; Montreal, Canada · 110 sites in all
- A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through MenopausePivotal-lookingCompleted
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT04003155 · 527 participants · Start Jul 11, 2019 · Primary completion Oct 29, 2020
Drug: fezolinetant; placebo · For: Hot Flashes
Sites: Andalusia, Alabama; Birmingham, Alabama; Ensley, Alabama · 96 sites in all
- A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2Pivotal-lookingCompleted
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT04003142 · 501 participants · Start Jul 10, 2019 · Primary completion Jul 30, 2020
Drug: Fezolinetant; placebo · For: Hot Flashes
Sites: Mesa, Arizona; Phoenix, Arizona; Tucson, Arizona · 93 sites in all
- A Study of Fezolinetant to Treat Hot Flashes in Women Going Through MenopausePivotal-lookingCompleted
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT05033886 · 453 participants · Start Nov 8, 2021 · Primary completion Mar 27, 2023
Drug: fezolinetant; placebo · For: Vasomotor Symptoms
Sites: Tienen, Belgium; Brampton, Canada; London, Canada · 69 sites in all
- A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through MenopausePivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT06206408 · 410 participants · Start Feb 16, 2024 · Primary completion Oct 22, 2025
Drug: Fezolinetant; Placebo · For: Hot Flashes
Sites: Chita-gun, Japan; Kōnan, Japan; Nagoya, Japan · 64 sites in all
- A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)Pivotal-lookingCompleted
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT03192176 · 356 participants · Start Jul 19, 2017 · Primary completion Sep 19, 2018
Drug: Fezolinetant; Placebo · For: Menopause; Hot Flashes
Sites: Anniston, Alabama; Birmingham, Alabama; Phoenix, Arizona · 51 sites in all
- A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through MenopausePivotal-lookingCompleted
Astellas Pharma China, Inc.Astellas (ALPMY)
NCT04234204 · 302 participants · Start Mar 17, 2020 · Primary completion Apr 20, 2022
Drug: Fezolinetant; Placebo · For: Hot Flashes
Sites: Beijing, China; Changchun, China; Changsha, China · 48 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective281
- hepatic enzyme increased217
- alanine aminotransferase increased200
- aspartate aminotransferase increased153
- headache130
- off label use124
- nausea110
- hot flush107
- liver function test increased98
- insomnia94
- diarrhoea86
- fatigue84
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 186 |
| 2024 | 736 |
| 2025 | 800 |
| 2026 | 576 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Veozah (Fezolinetant)
2024 spending
$38.4M
Beneficiaries
13,805
52,827 claims
Per beneficiary
$2,784
$17.77 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $4,494,558 |
| 2024 | $38,434,966 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
Johnson KA, Martin N, Nappi RE, et al. · J Clin Endocrinol Metab 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
Lederman S, Ottery FD, Cano A, et al. · Lancet 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
Morga A, Ajmera M, Gao E, et al. · Menopause 2024 · Systematic Review, Network Meta-Analysis
- Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis.
Menegaz de Almeida A, Oliveira P, Lopes L, et al. · Obstet Gynecol 2025 · Systematic Review, Meta-Analysis
- Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.
Neal-Perry G, Cano A, Lederman S, et al. · Obstet Gynecol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial.
Schaudig K, Wang X, Bouchard C, et al. · BMJ 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Astellas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.